AAAAAA
Results:
1-14
|
Results: 14
Authors:
Sanz-Altamira, PM
O'Reilly, E
Stuart, KE
Raeburn, L
Steger, C
Kemeny, NE
Saltz, LB
Citation: Pm. Sanz-altamira et al., A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma, ANN ONCOL, 12(4), 2001, pp. 501-504
Authors:
Saltz, LB
Miller, LL
Citation: Lb. Saltz et Ll. Miller, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer - Reply, N ENG J MED, 344(4), 2001, pp. 306-307
Authors:
O'Reilly, EM
Stuart, KE
Sanz-Altamira, PM
Schwartz, GK
Steger, CM
Raeburn, L
Kemeny, NE
Kelsen, DP
Saltz, LB
Citation: Em. O'Reilly et al., A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma, CANC CYTOP, 91(1), 2001, pp. 101-105
Authors:
O'Reilly, EM
Stuart, KE
Sanz-Altamira, PM
Schwartz, GK
Steger, CM
Raeburn, L
Kemeny, NE
Kelsen, DP
Saltz, LB
Citation: Em. O'Reilly et al., A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma, CANCER, 91(1), 2001, pp. 101-105
Authors:
Saltz, LB
Citation: Lb. Saltz, Regional strategies for managing hepatocellular carcinoma - The Venook article reviewed, ONCOLOGY-NY, 14(3), 2000, pp. 354
Authors:
Alektiar, KM
Zelefsky, MJ
Paty, PB
Guillem, J
Saltz, LB
Cohen, AM
Minsky, BD
Citation: Km. Alektiar et al., High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer, INT J RAD O, 48(1), 2000, pp. 219-226
Authors:
Saltz, LB
Cox, JV
Blanke, C
Rosen, LS
Fehrenbacher, L
Moore, MJ
Maroun, JA
Ackland, SP
Locker, PK
Pirotta, N
Elfring, GL
Miller, LL
Citation: Lb. Saltz et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer., N ENG J MED, 343(13), 2000, pp. 905-914
Authors:
Saltz, LB
Citation: Lb. Saltz, Failure to confirm major objective antitumor activity for streptozocin anddoxorubicin in the treatment of patients with advanced islet cell carcinoma - Author reply, CANCER, 88(9), 2000, pp. 2195-2195
Authors:
O'Reilly, EM
Ilson, DH
Saltz, LB
Heelan, R
Martin, L
Kelsen, DP
Citation: Em. O'Reilly et al., A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma, CANCER INV, 17(3), 1999, pp. 195-200
Authors:
Eads, CA
Danenberg, KD
Kawakami, K
Saltz, LB
Danenberg, PV
Laird, PW
Citation: Ca. Eads et al., CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. (vol 59, pg 2302, 1999), CANCER RES, 59(22), 1999, pp. 5860-5860
Authors:
Eads, CA
Danenberg, KD
Kawakami, K
Saltz, LB
Danenberg, PV
Laird, PW
Citation: Ca. Eads et al., CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression, CANCER RES, 59(10), 1999, pp. 2302-2306
Authors:
Cheng, PNM
Saltz, LB
Citation: Pnm. Cheng et Lb. Saltz, Failure to confirm major objective antitumor activity for streptozocin anddoxorubicin in the treatment of patients with advanced islet cell carcinoma, CANCER, 86(6), 1999, pp. 944-948
Authors:
Enzinger, PG
Ilson, DH
Saltz, LB
Martin, LK
Kelsen, DP
Citation: Pg. Enzinger et al., Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a inpatients with advanced esophageal carcinoma, CANCER, 85(6), 1999, pp. 1213-1217
Authors:
Saltz, LB
Spriggs, D
Schaaf, LJ
Schwartz, GK
Ilson, D
Kemeny, N
Kanowitz, J
Steger, C
Eng, M
Albanese, P
Semple, D
Hanover, CK
Elfring, GL
Miller, LL
Kelsen, D
Citation: Lb. Saltz et al., Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors, J CL ONCOL, 16(12), 1998, pp. 3858-3865
Risultati:
1-14
|